GrantZIANCI Division of Basic Sciences (intramural)
Regulation and Function of WIP1 Phosphatase and its Role in Tumor Cells
- Activity
- ZIA
- Institute
- NCI Division of Basic Sciences (intramural)
- Fiscal years counted
- 2018–2024
- Amount counted
- $5,662,758
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Abstract public domain (NIH RePORTER)
The wild-type p53-induced phosphatase Wip1 (PP2Cdelta or PPM1D) is a member of the serine/threonine protein phosphatase 2C (PP2C) family. Although Wip1 is expressed at low levels in most normal cells, its transcription is induced by p53 after exposure of cells to DNA damage-inducing agents, such as ionizing radiation (IR) or ultraviolet (UV) light. The Wip1 protein is frequently overexpressed or the PPM1D gene is amplified in several human cancers, and this increased expression is associated with worse outcomes. Studies on human cells have shown that overexpression of Wip1 compromises tumor suppressor functions, and studies of mice that lack Wip1 show that they are resistant to tumorigenesis. The current research on Wip1 is focused on understanding its regulation and functions, identifying its functional targets and performing high-throughput screens (HTS) of small molecule libraries to identify specific modulators of Wip1 phosphatase activity. In collaboration with Dr. Oleg Demidov (University of Burgundy, Dijon, France), we have used syngeneic tumor models to investigate the effects of ablating Wip1 in the immune system on tumor progression. We found that myeloid-specific deletion of Wip1 delayed the growth of both B10 melanoma tumors and LLC1 lung cancer tumors, confirming an important role of Wip1-deficient innate immune cells in anti-tumor immunity. Trying to elucidate those findings in more detail, we used a mouse with a specific ablation of Wip1 in neutrophils by crossbreeding our Ppm1d floxed mice (tm1c) with mice expressing the cre recombinase under the control of the mrp8 promoter, a protein specifically expressed in neutrophils (tm1c/mrp8cre). LLC1 cells injected subcutaneously showed decreased tumor growth when injected into tm1c/mrp8cre mice compared to tm1c mice. This decrease in growth was accompanied by an increased neutrophil infiltration, and a switch from N2 pro-tumoral neutrophils to N1 anti-tumor neutrophils. We are currently using global genomic methods to better understand the impact of Wip1 deletion in neutrophils. Determination of a high-resolution structure of the Wip1 catalytic domain that includes the conformation of the B-loop would greatly aid further development of specific inhibitors of Wip1 phosphatase activity. Additionally, high-resolution structural information for the Wip1 catalytic site would be useful for further optimization of known inhibitors and activators and to guide structure-activity investigations. To that end, we have obtained the first crystal structure of the PPM1D catalytic domain to 1.8 A resolution. The structure reveals the active site with two Mg2+ ions bound. It contains a high concentration of aspartic acid residues, closely resembling the active sites of other PPM family isoforms. The flap subdomain and B-loop, which are crucial for substrate recognition and catalysis, were also resolved, with the flap forming two short helices and three short B-strands that are followed by an irregular loop. Further, a polyethylene glycol (PEG) molecule was observed occupying the substrate groove and interacting directly with Arg18 and indirectly with Gly108, Glu22, and Phe268 via hydrogen-bonding bridges. The PEG mimics the substrate position within the PPM1D active site, extending from the phosphorylated residue to the next residue in the C-terminal direction. The highly conserved flap segment (269-LAVAR-273) runs alongside the active site, emphasizing its significance in maintaining active site integrity. A nitrogen-oxygen-sulfur bridge was identified in the catalytic domain, the first for the PPM family. Molecular dynamics simulations and kinetic studies provided mechanistic insights into the regulation of PPM1D catalytic activity. In addition, the kinetic experiments demonstrated a magnesium concentration-dependent lag in PPM1D attaining steady-state velocity, a feature of hysteretic enzymes that show slow transitions compared with catalytic turnover.
Abstract public domain (NIH RePORTER)
The structure and kinetic studies were recently published in the Journal of Biology Chemistry. As Wip1 is amplified or overexpressed in numerous human cancers including breast cancer, ovarian clear cell carcinoma, gastric cancer, pancreatic adenocarcinoma, medulloblastoma, and neuroblastoma, developing inhibitors of Wip1 activity may be beneficial in the treatment of several human cancers. Wip1, though, can function as a tumor suppressor in cancer cells bearing inactive mutated p53. Therefore, developing activators of Wip1 is as important as characterizing inhibitors of this phosphatase. We have developed and validated two orthogonal plate-based Wip1 activity assays for high-throughput screen (HTS). The two assays have high sensitivity and broad dynamic range enabled by either fluorescence detection or mass spectrometry and are suitable for screening compound libraries for modulators of Wip1 activity. In collaboration with the National Center for Advancing Translational Sciences (NCATS), we have used the above-mentioned HTS method to screen 102,277 compounds at a single concentration from the NCATS Genesis library using physiologically relevant substrates to identify Wip1 modulators. Hits were evaluated over a range of 11 concentrations with both the Rapid-Fire MS assay and the orthogonal fluorescence-based assay. Further biophysical, biochemical, and cell-based studies of confirmed hits revealed a Wip1 activator and two inhibitors, one competitive and one uncompetitive. All three compounds were further tested in a cell-based assay, in which yH2AX was assessed as a readout of WIP1 activity. Interestingly, only the competitive inhibitor showed a significant difference compared to the DMSO-treated cells. Currently, starting with the crystal structure that we have recently determined we are using virtual screening to identify binding sites of both inhibitors and activators, and search for new candidates from databases.